Edition:
United States

People: ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

2.34USD
2:12pm EST
Change (% chg)

$-0.17 (-6.77%)
Prev Close
$2.51
Open
$2.60
Day's High
$2.72
Day's Low
$2.18
Volume
326,597
Avg. Vol
232,842
52-wk High
$5.24
52-wk Low
$1.91

Pagan, Douglas 

Mr. Douglas W. Pagan is an Independent Director of the Company. Mr. Pagan is currently serves as Chief Financial Officer of Paratek Pharmaceuticals, Inc., a position he has held since December 2014, where he is responsible for fundraising, financial reporting, investor relations, and strategic planning. Prior to that, Mr. Pagán served as Vice President, Finance at Acceleron Pharma Inc., which he joined in 2008. There, he was responsible for strategic and financial planning, accounting, SEC reporting, treasury and financial operations, including undertaking a significant role in the company’s initial public offering. Prior to working at Acceleron, Mr. Pagán served in strategic and financial management roles at Biogen Idec and Bristol-Myers Squibb. Previously, Mr. Pagán worked in healthcare investment banking at J.P. Morgan, as well as pharmaceutical operational roles at Johnson & Johnson. Mr. Pagán received his B.S.E. in Chemical Engineering from Princeton University and his M.B.A. from Columbia Business School. Mr. Pagán is 46 years old. The board believes that Mr. Pagán’s experience as a financial executive in life science and pharmaceutical companies, as well as his prior investment banking experience, will allow Mr. Pagan to provide financial and strategic guidance to the Company and qualifies him to serve on the board.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Laurence Cooper

2,594,240

Kevin Lafond

581,224

David Mauney

2,297,970

Lynn Ferrucci

--

Scott Tarriff

128,178

James Cannon

129,448
As Of  30 Dec 2017